Last reviewed · How we verify

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A

City of Hope Medical Center · Phase 1 active Biologic Quality 0/100

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: 64Cu-DOTA-M5A, Cu 64-M5A.

At a glance

Generic nameCopper Cu 64 Anti-CEA Monoclonal Antibody M5A
Also known as64Cu-DOTA-M5A, Cu 64-M5A
SponsorCity of Hope Medical Center
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Copper Cu 64 Anti-CEA Monoclonal Antibody M5A

What is Copper Cu 64 Anti-CEA Monoclonal Antibody M5A?

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A is a Biologic drug developed by City of Hope Medical Center.

Who makes Copper Cu 64 Anti-CEA Monoclonal Antibody M5A?

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is Copper Cu 64 Anti-CEA Monoclonal Antibody M5A also known as anything else?

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A is also known as 64Cu-DOTA-M5A, Cu 64-M5A.

What development phase is Copper Cu 64 Anti-CEA Monoclonal Antibody M5A in?

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A is in Phase 1.

Related